Sofosbuvir + Velpatasvir
Yes
No
Standard Drug List
Active ingredients: Sofosbuvir | Velpatasvir
General information
Subsidy Information and Financing Scheme
Drug Guidance for Subsidy
04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C
The Ministry of Health’s Drug Advisory Committee has recommended:
Sofosbuvir 400 mg/velpatasvir 100 mg tablets
in line with its registered indications for treating chronic hepatitis C.
Funding status
[R] Sofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024.
[NR] Of note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
